Evopoint Biosciences
PrivateLast Round
Series E
Feb 20, 2024
Est. Valuation
$752.3M
Total Funding Raised
$242.2M
Company Overview
Evopoint Biosciences operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series E round in February 2024.
Evopoint Biosciences is a biopharmaceutical company that develops therapies for oncology, infectious diseases, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Evopoint Biosciences Comparables
Compare Evopoint Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Teligene | 66% | |
| Nodus Oncology | 54% | |
| Crystalys Therapeutics | 54% |
For institutional investors. Book with your work email.
Evopoint Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Feb 20, 2024 | ||||
| Series D | Dec 31, 2020 | ||||
| Series C | Aug 25, 2020 | ||||
| Series B | Jun 26, 2019 | ||||
| Series A | May 24, 2018 | ||||
Angel | Nov 1, 2017 |
For institutional investors. Book with your work email.
Evopoint Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tencent Exploration | Series E |
| Loyal Valley Capital | Series E, Series A, Series C |
| Agricultural Bank of China International | Series D |
| Jinan Industrial Development Investment Group | Series E |
| Chenhai Capital | Series E |
| Jiuyou Capital | Series D, Series C |
| Oceanpine Capital | Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 31, 2020
Led by Oceanpine Capital with participation from Agricultural Bank of China International.
- Aug 25, 2020
$145M round led by Loyal Valley Capital.
For institutional investors. Book with your work email.
Evopoint Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Evopoint Biosciences's valuation, stock price, and market status.
Is Evopoint Biosciences a public or private company?
Evopoint Biosciences is a private company.
What is the current stock price of Evopoint Biosciences?
Evopoint Biosciences is a private company, so its shares have no public market price. Caplight tracks Evopoint Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Evopoint Biosciences worth (valuation)?
Evopoint Biosciences's valuation is estimated at $752.3M based on funding round data.
Can I buy Evopoint Biosciences stock?
Evopoint Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Evopoint Biosciences's last funding round?
Evopoint Biosciences's most recent funding round was Series E on February 20, 2024.
Who are the main investors in Evopoint Biosciences?
Key investors in Evopoint Biosciences include Tencent Exploration, Loyal Valley Capital, Oceanpine Capital.
Will Evopoint Biosciences IPO soon?
No public IPO plans have been announced for Evopoint Biosciences.
How can I track Evopoint Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Evopoint Biosciences's shares on secondary markets.